ClinicalTrials.gg
CompletedNCT02225665Updated Mar 19, 2021Results posted

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

A Phase 1/2 interventional study of SB-728mR-T and SB-728mR-T in Human Immunodeficiency Virus (HIV), sponsored by Sangamo Therapeutics. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-19.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Sangamo Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability of repeat doses of T-cell immunotherapy (SB-728mR-T) following cyclophosphamide conditioning.

CCR5 is a major co-receptor for HIV entry into T-cells. Disruption of CCR5 by zinc finger nuclease (SB-728mR), blocks HIV entry into the T-cells, therefore, protects the T-cells from HIV infection. Safety (primary outcome) and anti-viral effect (secondary outcome) of zinc finger nuclease-mediated CCR5 disrupted autologous T-cells (SB-728mR-T) will be evaluated in the study.

02

Conditions studied

  • Human Immunodeficiency Virus (HIV)

Browse trials for

03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 8 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Sangamo Therapeutics is the lead sponsor of 28 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years of age or older with documented diagnosis.
  • Must be willing to comply with study-mandated evaluations; including discontinuation of current antiretroviral therapy during the treatment interruption.
  • Initiated HAART therapy within (≤) 1 year of HIV diagnosis or suspected infection.
  • Undetectable HIV-1 RNA for at least 2 months prior to screening and at screening.
  • ≥500 cells/µL.
  • (ANC) ≥ 2500/mm3.
  • count ≥ 200,000/mm3.

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic or infection.
  • Active or recent (in prior 6 months) AIDS defining complication.
  • Any cancer or within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin or low grade (0 or 1) anal or cervical dysplasia.
  • Current diagnosis of grade 3 or 4 CHF, uncontrolled angina or uncontrolled arrhythmias.
  • History or any features on physical examination indicative of a bleeding diathesis.
  • Received experimental vaccine within 6 months prior to screening, or any previous gene therapy using an integrating vector.
  • Use of chronic , hydroxyurea, or immunomodulating agents within 30 days prior to screening.
  • Use of Aspirin, dipyridamole, warfarin or any other medication that is likely to affect function or other aspects of blood coagulation during the 2 week period prior to leukapheresis.
  • Currently participating in another clinical trial or participation in such a trial within 30 days prior to screening visit.
  • Currently taking maraviroc or have received maraviroc within 6 months prior to screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Genetic: SB-728mR-T · Drug: Cyclophosphamide

  • Experimental
    Cohort 2

    Genetic: SB-728mR-T · Drug: Cyclophosphamide

Interventions

  • GeneticSB-728mR-T

    -SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)

  • GeneticSB-728mR-T

    - SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)

  • - IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measure

    Number of Participants with Treatment related Adverse Events in subjects who received any portion of the SB-728mR-T infusion

    Time frame: 12 months

Secondary outcomes

  1. Secondary Outcome Measure

    Effect of repeat doses of SB-728mR-T on engraftment following cyclophosphamide conditioning as measured by CCR5 Modified CD4 Cells at Month 12.

    Time frame: 12 months

  2. Secondary Outcome Measure

    Effect of SB-728mR-T on plasma HIV-1 RNA levels following HAART interruption

    Time frame: 12 months

  3. Secondary Outcome Measure

    Change from baseline to month 12 in CD4+ T-cell counts in peripheral blood after repeat treatments with SB-728mR-T. (i.e. month 12 value - baseline value)

    Time frame: Baseline and 12 months

07

Results

Posted Feb 9, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started35
Completed24
Not completed11
Withdrew: Subject moved from area and finds it difficult to return for visits.10
Withdrew: Subject restarted haart prior to month 18.01

Outcome measures

PrimaryPrimary Outcome Measure

Number of Participants with Treatment related Adverse Events in subjects who received any portion of the SB-728mR-T infusion

Time frame:
12 months
Reported as:
Count of participants · Participants
Primary Outcome Measure
ParticipantsCohort 1Cohort 2
Primary Outcome Measure12
SecondarySecondary Outcome Measure

Effect of repeat doses of SB-728mR-T on engraftment following cyclophosphamide conditioning as measured by CCR5 Modified CD4 Cells at Month 12.

Time frame:
12 months
Reported as:
Mean · cells 10^9/L
Secondary Outcome Measure
cells 10^9/LCohort 1Cohort 2
Secondary Outcome Measure0.090 ± 0.00150.162 ± 0.0818
SecondarySecondary Outcome Measure

Effect of SB-728mR-T on plasma HIV-1 RNA levels following HAART interruption

Time frame:
12 months
Reported as:
Mean · log copies/mL
Secondary Outcome Measure
log copies/mLCohort 1Cohort 2
Secondary Outcome Measure3.218 ± 1.92431.228 ± 1.7029
SecondarySecondary Outcome Measure

Change from baseline to month 12 in CD4+ T-cell counts in peripheral blood after repeat treatments with SB-728mR-T. (i.e. month 12 value - baseline value)

Time frame:
Baseline and 12 months
Reported as:
Mean · cells 10^9/L
Secondary Outcome Measure
cells 10^9/LCohort 1Cohort 2
Secondary Outcome Measure-0.178 ± 0.04450.078 ± 0.2796

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/3 (0%)0/3 (0%)3/3 (100%)
Cohort 20/5 (0%)0/5 (0%)5/5 (100%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventCohort 1Cohort 2
AlopeciaSkin and subcutaneous tissue disorders1/32/5
Skin odour abnormalSkin and subcutaneous tissue disorders0/32/5
DiarrhoeaGastrointestinal disorders1/30/5
PyrexiaGeneral disorders1/30/5
NasopharyngitisInfections and infestations1/30/5
CachexiaMetabolism and nutrition disorders1/30/5
Muscle spasmsMusculoskeletal and connective tissue disorders1/30/5
NephrolithiasisRenal and urinary disorders1/30/5
RashSkin and subcutaneous tissue disorders1/31/5
Gastric ulcerGastrointestinal disorders0/31/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Total
Mean59.0 ± 8.1939.6 ± 10.0946.9 ± 13.35
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female101
Male257
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Total
Hispanic or Latino011
Not Hispanic or Latino347
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White347
More than one race000
Unknown or Not Reported000
08

Study locations

5 sites
  • San Francisco, California 94115, United States
  • Norwalk, Connecticut 06850, United States
  • Orlando, Florida 32803, United States
  • Austin, Texas 78705, United States
  • Dallas, Texas 75246, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Jun 2018, 46 months.

Results were first posted in Feb 2021, 2 years 8 months after primary completion.

Of 29 phase 1/2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 24. This study's 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2014
First posted
Aug 26, 2014
StartActual
Aug 2014
Primary completionActual
Jun 2018
CompletionActual
Jun 2018
Results first posted
Feb 9, 2021
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02225665
Responsible party
Sponsor
First posted
Aug 26, 2014
Start date
Aug 2014
Primary completion
Jun 2018
Completion
Jun 2018
Results posted
Feb 9, 2021
Last update
Mar 19, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclophosphamide

Start the discussion